Real‐time impact of COVID‐19 pandemic on cutaneous leishmaniasis case finding and strategic planning, preventive interventions, control and epidemiology in a region with a high burden of cutaneous leishmaniasis and COVID‐19: A cross‐sectional descriptive study based on registry data in Ilam‐Iran
暂无分享,去创建一个
A. Kenarkoohi | S. Falahi | A. Abdoli | J. Mohamadi | R. Pakzad | J. Abdi | M. Shams | N. Maspi | R. Naserifar | A. Bozorgomid | Ayoub Rashidi | Mohamad Moradi | Fariba Ghelichi | Yasin Mohammadi
[1] M. Barrett,et al. Drug resistance in Leishmania: does it really matter? , 2023, Trends in parasitology.
[2] S. Falahi,et al. Systematic Review and Meta-analysis of Role of Felids as Intermediate Hosts in the Life Cycle of Neospora caninum Based on Serological Data , 2023, Acta Parasitologica.
[3] S. Falahi,et al. Assessment of genetic markers for multilocus sequence typing (MLST) of Fasciola isolates from Iran , 2022, Veterinary medicine and science.
[4] A. Kenarkoohi,et al. Immunogenicity of COVID‐19 mRNA vaccines in hemodialysis patients: Systematic review and meta‐analysis , 2022, Health science reports.
[5] A. Kenarkoohi,et al. COVID-19 Mass Vaccination and Flu season: Concern for Decreased Public Health Measures and worsening the influenza situation. , 2022, Infectious disorders drug targets.
[6] A. Abdoli,et al. Outbreak of cutaneous leishmaniasis before and during the COVID-19 pandemic in Jahrom, an endemic region in the southwest of Iran , 2022, Emerging microbes & infections.
[7] A. Kenarkoohi,et al. Sufficient Sleep, Time of Vaccination, and Vaccine Efficacy: A Systematic Review of the Current Evidence and a Proposal for COVID-19 Vaccination , 2022, The Yale journal of biology and medicine.
[8] A. Kenarkoohi,et al. COVID-19 vaccination, Peltzman Effect and possible increase in high-risk behaviors: a growing concern on risk compensation and reduced compliance to Public Health protective Measures after vaccines rollout. , 2022, Infectious disorders drug targets.
[9] M. Shirzadi,et al. Fifty years of struggle to control cutaneous leishmaniasis in the highest endemic county in Iran: A longitudinal observation inferred with interrupted time series model , 2022, PLoS neglected tropical diseases.
[10] F. Najafi,et al. Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study , 2022, BMC Infectious Diseases.
[11] A. Kenarkoohi,et al. An update review on complicated mechanisms of COVID-19 pathogenesis and therapy: direct viral damage, renin-angiotensin system dysregulation, immune system derangements, and endothelial dysfunction. , 2022, Infectious disorders drug targets.
[12] A. Kenarkoohi,et al. Interleukin‐29 profiles in COVID‐19 patients: Survival is associated with IL‐29 levels , 2022, Health science reports.
[13] A. Kenarkoohi,et al. Changes in Physiological Levels of Cortisol and Adrenocorticotropic Hormone upon Hospitalization Can Predict SARS-CoV-2 Mortality: A Cohort Study , 2022, International journal of endocrinology.
[14] M. Gramiccia,et al. Surveillance of leishmaniasis cases from 15 European centres, 2014 to 2019: a retrospective analysis , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[15] S. Rodríguez-Couto,et al. Socio-Environmental Determinants and Human Health Exposures in Arid and Semi-Arid Zones of Iran—Narrative Review , 2022, Environmental health insights.
[16] Özlem Ulusan Bağcı. Impact of the COVID-19 Duration on Neglected Parasitic Diseases. , 2021, Turkiye parazitolojii dergisi.
[17] A. Kenarkoohi,et al. Host factors and vaccine efficacy: Implications for COVID‐19 vaccines , 2021, Journal of medical virology.
[18] P. Saberian,et al. Changes in COVID-19 IgM and IgG antibodies in emergency medical technicians (EMTs) , 2021, The American Journal of Emergency Medicine.
[19] A. Azman,et al. Towards global control of parasitic diseases in the Covid-19 era: One Health and the future of multisectoral global health governance , 2021, Advances in Parasitology.
[20] P. Bonan,et al. COVID-19 Pandemic Causes Increased Clinic Visits with Diagnosis of Tegumentary Leishmaniasis in Brazil in 2020 , 2021, International Journal of Infectious Diseases.
[21] M. Azage,et al. Effect of the COVID-19 Pandemic Preparation and Response on Essential Health Services in Primary and Tertiary Healthcare Settings of Amhara Region, Ethiopia , 2021, The American journal of tropical medicine and hygiene.
[22] S. Falahi,et al. Outcome evaluation of COVID-19 infected patients by disease symptoms: a cross-sectional study in Ilam Province, Iran , 2021, BMC Infectious Diseases.
[23] R. Cantón,et al. COVID-19: Impact on prescribing and antimicrobial resistance , 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[24] A. Kenarkoohi,et al. Environmental Surface Contamination with SARS-CoV-2: Toilets as the Most Contaminated Surfaces in COVID-19 Referral Hospital , 2021, Hospital topics.
[25] A. Kenarkoohi,et al. COVID-19-associated opportunistic infections: a snapshot on the current reports , 2021, Clinical and Experimental Medicine.
[26] T. Dzieciątkowski,et al. The New Status of Parasitic Diseases in the COVID-19 Pandemic—Risk Factors or Protective Agents? , 2021, Journal of clinical medicine.
[27] A. Kenarkoohi,et al. Prevalence and clinical presentation of COVID-19 infection in hemodialysis patients , 2021, Journal of Nephropathology.
[28] D. C. Miguel,et al. The impact of COVID-19 on neglected parasitic diseases: what to expect? , 2021, Trends in Parasitology.
[29] S. Fauziyah,et al. How should Indonesia consider its neglected tropical diseases in the COVID-19 era? Hopes and challenges (Review) , 2021, Biomedical reports.
[30] V. Ziaee,et al. Clinical Misdiagnosis of COVID-19 Infection with Confusing Clinical Course , 2021, Case reports in infectious diseases.
[31] A. Kenarkoohi,et al. Claims and reasons about mild COVID-19 in children , 2021, New Microbes and New Infections.
[32] F. Bahrami,et al. Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis. , 2021, Microbial pathogenesis.
[33] M. Saraei,et al. Cutaneous leishmaniasis as an increasing threat for Iranian travellers attending religious ceremonies. , 2021, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[34] A. Rezaie,et al. The potential therapeutic effect of adipose-derived mesenchymal stem cells in the treatment of cutaneous leishmaniasis caused by L. major in BALB/c mice. , 2021, Experimental parasitology.
[35] K. Ghadiri,et al. Prevalence of human visceral leishmaniasis in Iran: A systematic review and meta-analysis. , 2020, Comparative immunology, microbiology and infectious diseases.
[36] Mirza Ali Mofazzal Jahromi,et al. Infections, inflammation, and risk of neuropsychiatric disorders: the neglected role of “co-infection” , 2020, Heliyon.
[37] A. Abdoli,et al. Iran, sanctions, and the COVID-19 crisis , 2020, Journal of medical economics.
[38] L. Coffeng,et al. Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India , 2020, medRxiv.
[39] Shahab Falahi,et al. Transmission routes for SARS-CoV-2 infection: review of evidence , 2020, New Microbes and New Infections.
[40] Michael S. Deiner,et al. Predicted Impact of COVID-19 on Neglected Tropical Disease Programs and the Opportunity for Innovation , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] M. B. Eslaminejad,et al. Therapeutic effects of Mesenchymal Stem Cells on Cutaneous Leishmaniasis Lesions caused by Leishmania major. , 2020, Journal of global antimicrobial resistance.
[42] S. Mohammadi,et al. The prevalence of human bocavirus in <2-year-old children with acute bronchiolitis , 2020, New microbes and new infections.
[43] A. Picado,et al. Diagnosis of neglected tropical diseases during and after the COVID-19 pandemic , 2020, PLoS neglected tropical diseases.
[44] F. Karaca,et al. Impact of COVID-19 Event on the Air Quality in Iran , 2020 .
[45] M. Soleimani,et al. HSV-TK Expressing Mesenchymal Stem Cells Exert Inhibitory Effect on Cervical Cancer Model , 2020, International journal of molecular and cellular medicine.
[46] A. Kenarkoohi,et al. Report of 5 nurses infecting COVID-19 during patient care: case Series , 2020, New Microbes and New Infections.
[47] A. Kenarkoohi,et al. The COVID-19 pandemic, psychological stress during pregnancy, and risk of neurodevelopmental disorders in offspring: a neglected consequence , 2020, Journal of psychosomatic obstetrics and gynaecology.
[48] S. Soudi,et al. Repeated intravenous injection of adipose tissue derived mesenchymal stem cells enhances Th1 immune responses in Leishmania major-infected BALB/c mice. , 2019, Immunology letters.
[49] D. Sandoval,et al. Autochthonous cutaneous leishmaniasis in urban domestic animals (Felis catus / Canis lupus familiaris) from central-western Venezuela. , 2019, Acta tropica.
[50] N. Nazari,et al. Cutaneous leishmaniasis in Qasr-e Shirin, a border area in the west of Iran , 2018, Veterinary world.
[51] Mohammad Reza Aflatoonian,et al. A newly emerged focus of zoonotic cutaneous leishmaniasis in South-western Iran. , 2018, Microbial pathogenesis.
[52] J. Abdi,et al. Seroprevalence of Toxocara in Children from Urban and Rural Areas of Ilam Province, West Iran , 2018, Osong public health and research perspectives.
[53] M. Booth. Climate Change and the Neglected Tropical Diseases , 2018, Advances in Parasitology.
[54] A. Khamesipour,et al. Genetic Diversity and Phylogenetic Analysis of the Iranian Leishmania Parasites Based on HSP70 Gene PCR-RFLP and Sequence Analysis , 2017, The Korean journal of parasitology.
[55] A. Foroumadi,et al. Synthesis and Leishmanicidal Activity of 1-[5-(5-Nitrofuran-2-yl)-1, 3, 4-Thiadiazole-2-yl]-4-BenzoylePiperazines , 2017, Iranian journal of pharmaceutical research : IJPR.
[56] A. Campos-Neto,et al. CD271+ Mesenchymal Stem Cells as a Possible Infectious Niche for Leishmania infantum , 2016, PloS one.
[57] M. Gouya,et al. Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces , 2016 .
[58] J. Abdi,et al. Identification and determination of the prevalence of Toxoplasma gondii in patients with chronic renal failure by ELISA and PCR , 2016 .
[59] M. Shirzadi,et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. , 2015, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[60] M. Soleimani,et al. Efficient Lentiviral Transduction of Adipose Tissue-Derived Mouse Mesenchymal Stem Cells and Assessment of Their Penetration in Female Mice Cervical Tumor Model , 2014, Iranian journal of cancer prevention.
[61] B. Sarkari,et al. Knowledge, attitude, and practices related to cutaneous leishmaniasis in an endemic focus of cutaneous leishmaniasis, Southern Iran. , 2014, Asian Pacific journal of tropical biomedicine.
[62] Dylan B. George,et al. Global distribution maps of the leishmaniases , 2014, eLife.
[63] R. López-Vélez,et al. Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. , 2014, Travel medicine and infectious disease.
[64] M. Taran,et al. Larvicidal Effects of Essential Oil and Methanolic Extract of Hymenocarter longiflorus (Lamiaceae ) Against Echinococcus granulosus , 2013 .
[65] S. Falahi,et al. Phylogenetic Analysis of Torque Teno Virus in Hepatitis C Virus Infected Patients in Shiraz , 2012, Hepatitis monthly.
[66] M. Nilforoushzadeh,et al. The knowledge, attitude, and prevention practices of students regarding cutaneous leishmaniasis in the hyperendemic region of the Shahid Babaie Airbase. , 2012, Vector borne and zoonotic diseases.
[67] Hossein Riahi Madvar,et al. Prediction of hepatitis B virus lamivudine resistance based on YMDD sequence data using an artificial neural network model , 2011 .
[68] A. Khorsandi,et al. EPIDEMIOLOGY OF CUTANEOUS LEISHMANIASIS IN DAMGHAN DISTRICT , 2010 .
[69] M. Bandehpour,et al. Serological Evaluation of EgAgB16 kDa, a Recombinant Antigen from Echinococcus granulosus for Diagnosis of Human Hydatidosis , 2010, Iranian journal of parasitology.
[70] P J Hotez,et al. Mass Drug Administration and Integrated Control for the World's High‐Prevalence Neglected Tropical Diseases , 2009, Clinical pharmacology and therapeutics.
[71] R. Mirnejad,et al. Epidemic Assessment of Bacterial Agents in Osteomyelitis and Their Antibiotic Resistance Pattern Determination , 2008 .
[72] H. Najmabadi,et al. Fourteen-Year Experience of Prenatal Diagnosis of Thalassemia in Iran , 2006, Public Health Genomics.
[73] J. Berman,et al. Advances in leishmaniasis , 2005, The Lancet.
[74] A. Akhavan,et al. Rodent control operations against zoonotic cutaneous leishmaniasis in rural Iran , 2005, Annals of Saudi medicine.
[75] P. Desjeux. Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.
[76] F. Modabber,et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan , 2000, The Lancet.
[77] A. Khamesipour,et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran , 1998, The Lancet.
[78] S. Croft,et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis , 1991, The Lancet.
[79] A. Kenarkoohi,et al. CLINICAL FEATURES OF NOVEL CORONAVIRUS 2019-INFECTED CASES WITH PRE-EXISTING CARDIOVASCULAR DISEASE, DISAGGREGATED BY GENDER , 2021 .
[80] A. Berg,et al. Present and future Köppen-Geiger climate classification maps at 1-km resolution. , 2018, Scientific data.
[81] LEISHMANIASIS Epidemiological Report of the Americas , 2018 .
[82] S. Brooker,et al. Cutaneous leishmaniasis. , 2007, The Lancet. Infectious diseases.